Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction

NCT01641939 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01641939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01641939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2/3
Overall status
Terminated
Start date
September 3, 2012
Completion date
April 30, 2016
Enrollment
415 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer